Premium
Management of severe congenital protein C deficiency with a direct oral anticoagulant, edoxaban: A case report
Author(s) -
Watanabe Kentaro,
Arakawa Yuki,
Yanagi Masato,
Isobe Kiyotaka,
Mori Makiko,
Koh Katsuyoshi
Publication year - 2019
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.27686
Subject(s) - medicine , edoxaban , pediatrics , oral anticoagulant , intensive care medicine , warfarin , dabigatran , atrial fibrillation
A male patient diagnosed with severe congenital protein C (PC) deficiency during the neonatal period was treated with long‐term warfarin but frequently developed purpura fulminans and bleeding. At four years of age, edoxaban was initiated (direct oral anticoagulant [DOAC]). His d ‐dimer and fibrin/fibrinogen degradation product levels were closely monitored. His PC activity increased from below the sensitivity range to 17%; this increase was thought to be due to a reduction in PC consumption during edoxaban therapy. After edoxaban introduction, he experienced just one episode of purpura fulminans over two years without any adverse events. Thus, DOAC may be a promising alternative for the management of congenital PC deficiency.